In Brief: Medical device reporting
This article was originally published in The Gray Sheet
Executive SummaryMedical device reporting: FDA stays effective date of certain portions of the annual baseline reporting requirement of the agency's December 1995 final manufacturer MDR rule. The stay, published in the July 31 Federal Register, applies to the number of devices manufactured, distributed or in use (so-called "denominator data"), which FDA had intended to use in determining the prevalence of adverse events. The agency is issuing the stay "until further notice" in response to device industry concerns about the provision. FDA will explore mechanisms for obtaining denominator data via a small-scale pilot project slated to begin this fall ("The Gray Sheet" July 15, p. 10). The remaining portions of the MDR rule became effective as scheduled July 31...
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.